Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 3—March 2007
Dispatch

Environmental Burkholderia cepacia Complex Isolates from Human Infections

Adam Baldwin*, Eshwar Mahenthiralingam†, Pavel Drevinek†, Peter Vandamme‡, John R. Govan§, David J. Waine*, John J. LiPuma¶, Luigi Chiarini#, Claudia Dalmastri#, Deborah A. Henry**, David P. Speert**, David Honeybourne††, Martin C. J. Maiden‡‡, and Chris G. Dowson*Comments to Author 
Author affiliations: *Warwick University, Coventry, Wales, United Kingdom; †Cardiff University, Cardiff, England, United Kingdom; ‡Universiteit Gent, Ghent, Belgium; §University of Edinburgh Medical School, Edinburgh, Scotland, United Kingdom; ¶University of Michigan Medical School, Ann Arbor, Michigan, USA; #Ente per le Nuove Tecnologie l’Energia e l’Ambiente Casaccia, Rome, Italy; **University of British Columbia, Vancouver, British Columbia, Canada; ††Birmingham Heartlands Hospital, Birmingham, England, United Kingdom; ‡‡University of Oxford, Oxford, England, United Kingdom;

Main Article

Table

MLST analysis of the Burkholderia cepacia strains showing their species, source, and geographic location*

Bcc species
ST
Isolate name
Source
Country
Source of isolate:
Year of isolation
B. cepacia
1ATCC 17759†ENVTrinidadSoil1958
1
LMG 14087
NON
UK
Wound
1988
10ATCC 25416TENVUSAOnion1948
10
J1050
NON
USA
Human
Before 1983
266BC20ENVUSAWater–
266
AU6671
NON
U.S.
Wound
–
365HI-3602ENVUSASoil–
365C8509CFCanadaSputum1999
365
AU3206
CF
USA
Sputum
–
B. multivorans
21ATCC 17616†ENVUSASoilBefore 1966
21AU0453CFUSASputum–
21
C9140
CF
Canada
Sputum
2000
375R-20526ENVBelgiumRiver water2002
375
IST455
CF
Portugal
Sputum
2000
B. cenocepacia IIIA
32POPR8ENVMexicoRadish–
325–457CFCzech RepublicSputum2002
32R-16597CFBelgiumSputum2001
32
BCC1118
NON
UK
Wound
Before 1994
B. cenocepacia IIIB
37BC-1ENVUSAMaize rhizosphere–
37
AU2362
CF
USA
Sputum
2000
122HI-2424ENVUSASoil–
122AU1054CFUSACF–
122
CEP0497
NON
Canada
Leg ulcer
1995
B. stabilis
50LMG 14294†CFBelgiumSputum1993
50R-16919ENVBelgiumIndustrial–
50
LMG 14086†
ENVH
UK
Respirator
1970
51HI-2482ENVUSAShampoo–
51ATCC 35254ENVHUSAMedical solution1980
51CEP0928ENVHUSAAlbuterol solution–
51LMG 14291CFBelgiumSputum1993
51
LMG 7000
NON
Sweden
Blood
1983
B. vietnamiensis
61J1702ENVHUSAHospital equipment–
61BCC0190CFUSASputum–
61J1712NONUSAWound–
61J1738NONUSAWound–
61
J1742
NON
USA
Wound
–
67R-20590ENVBelgiumRiver water2002
67
D0774
CF
Canada
Sputum
2003
B. ambifaria
81MVP-C2-4ENVItalyMaize rhizosphere1996
81
BCC0250†
CF
Australia
Sputum
1994
77AMMDTENVUSASoil1985
77AU0212CFUSASputum–

*MLST, multilocus sequence typing; Bcc, B. cepacia complex; ST, sequence type; ENV, isolated from the environment; NON, isolated from a non-cystic fibrosis (CF) patient; CF, isolated from a CF patient; IIIA or IIIB, isolates belonging to B. cenocepacia recA subgroup A or B, respectively; ENVH, isolated from a hospital environment.
†, panel strain (12); suprascript T, type strain for species.

Main Article

References
  1. Coenye T, Vandamme P, Govan JR, LiPuma JJ. Taxonomy and identification of the Burkholderia cepacia complex.J Clin Microbiol. 2001;39:3427–36. DOIPubMedGoogle Scholar
  2. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex.Nat Rev Microbiol. 2005;3:144–56. DOIPubMedGoogle Scholar
  3. Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.Lancet. 1993;342:15–9. DOIPubMedGoogle Scholar
  4. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis.Lancet. 1990;336:1094–6. DOIPubMedGoogle Scholar
  5. Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis.J Clin Microbiol. 1996;34:584–7.PubMedGoogle Scholar
  6. Oie S, Kamiya A. Microbial contamination of antiseptics and disinfectants.Am J Infect Control. 1996;24:389–95. DOIPubMedGoogle Scholar
  7. Holmes A, Govan J, Goldstein R. Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health?Emerg Infect Dis. 1998;4:221–7.PubMedGoogle Scholar
  8. LiPuma JJ, Mahenthiralingam E. Commercial use of Burkholderia cepacia.Emerg Infect Dis. 1999;5:305–6.PubMedGoogle Scholar
  9. Govan JRW, Balendreau J, Vandamme P. Burkholderia cepacia - Friend and foe.ASM News. 2000;66:124–5.
  10. LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil.Lancet. 2002;359:2002–3. DOIPubMedGoogle Scholar
  11. Baldwin A, Mahenthiralingam E, Thickett KM, Honeybourne D, Maiden MC, Govan JR, Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.J Clin Microbiol. 2005;43:4665–73. DOIPubMedGoogle Scholar
  12. Coenye T, Vandamme P, LiPuma JJ, Govan JR, Mahenthiralingam E. Updated version of the Burkholderia cepacia complex experimental strain panel.J Clin Microbiol. 2003;41:2797–8. DOIPubMedGoogle Scholar
  13. Cunha MV, Leitao JH, Mahenthiralingam E, Vandamme P, Lito L, Barreto C, Molecular analysis of Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis center: a 7-year study.J Clin Microbiol. 2003;41:4113–20. DOIPubMedGoogle Scholar
  14. Coenye T, Spilker T, Van Schoor A, LiPuma JJ, Vandamme P. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe.Thorax. 2004;59:952–4. DOIPubMedGoogle Scholar
  15. Vandamme P, Mahenthiralingam E, Holmes B, Coenye T, Hoste B, De Vos P, Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV).J Clin Microbiol. 2000;38:1042–7.PubMedGoogle Scholar

Main Article

Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external